An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan

Wei Chi Wu, Hsi Kung Kuo, Po Ting Yeh, Chung May Yang, Chi Chun Lai, San Ni Chen*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

110 引文 斯高帕斯(Scopus)

摘要

Purpose: To investigate the effectiveness and complications associated with the use of bevacizumab, an anti-vascular endothelial growth factor agent, in the treatment of prethreshold retinopathy of prematurity (ROP). Design: A multicenter, retrospective case series. Methods: Data from patients who had received intravitreal bevacizumab (IVB) injections for the treatment of ROP were collected from 4 medical centers in Taiwan. The main outcome measures were the regression of ROP and the complications that were associated with the IVB injections. Results: In total, 162 eyes from 85 patients were included in the study. After receiving IVB injections, 143 eyes (88%) exhibited ROP regression. Fourteen eyes (9%) required additional laser treatment for ROP regression after the absence of a positive response to the IVB injections. Three eyes (2%) progressed to stage 4 ROP and required vitrectomies to reattach the retinas. Two eyes (1%) received 1 additional IVB injection to decrease persistent plus disease. All of the eyes (100%) had attached retinas after the various treatments that they received. The major ocular complications that were associated with IVB injections included vitreous or preretinal hemorrhage in 2 eyes (1%); cataract in 1 eye (1%); and exotropia in 1 eye (1%). No notable systemic complications related to the IVB injections were observed. Conclusions: IVB injection seems to be an effective and well-tolerated method of treating prethreshold ROP. Laser therapy may still be required as a backup treatment for patients who do not respond to an IVB injection or for those in whom ROP worsens after an IVB injection.

原文英語
頁(從 - 到)150-158.e1
期刊American Journal of Ophthalmology
155
發行號1
DOIs
出版狀態已出版 - 01 2013

指紋

深入研究「An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan」主題。共同形成了獨特的指紋。

引用此